Recombinant Human VEGFR2/KDR Fc Chimera Protein, CF | R&D Systems 357-KD-050/CF product information

product summary

company name :

R&D Systems

product type :

protein

product name :

Recombinant Human VEGFR2/KDR Fc Chimera Protein, CF

catalog :

357-KD-050/CF

quantity :

50 ug

price :

443 USD

more info or order :

R&D Systems product webpage

citations: 40

Reference
Chuai M, Serrano N xe1 jera G, Serra M, Mahadevan L, Weijer C. Reconstruction of distinct vertebrate gastrulation modes via modulation of key cell behaviors in the chick embryo. Sci Adv. 2023;9:eabn5429 pubmed publisher
Yagolovich A, Artykov A, Isakova A, Vorontsova Y, Dolgikh D, Kirpichnikov M, et al. Optimized Heterologous Expression and Efficient Purification of a New TRAIL-Based Antitumor Fusion Protein SRH-DR5-B with Dual VEGFR2 and DR5 Receptor Specificity. Int J Mol Sci. 2022;23: pubmed publisher
Lu L, Chen H, Wang L, Zhao L, Cheng Y, Wang A, et al. A Dual Receptor Targeting- and BBB Penetrating- Peptide Functionalized Polyethyleneimine Nanocomplex for Secretory Endostatin Gene Delivery to Malignant Glioma. Int J Nanomedicine. 2020;15:8875-8892 pubmed publisher
Fujiwara K, Sasawatari S, Nakai S, Imaeda K, Nagai S, Matsuno Y, et al. Predicting the Efficacy and Safety of TACTICs (Tumor Angiogenesis-Specific CAR-T Cells Impacting Cancers) Therapy for Soft Tissue Sarcoma Patients. Cancers (Basel). 2020;12: pubmed publisher
Mamer S, Wittenkeller A, Imoukhuede P. VEGF-A splice variants bind VEGFRs with differential affinities. Sci Rep. 2020;10:14413 pubmed publisher
Seo H, Masuda H, Asagoshi K, Uchiki T, Kawata S, Sasaki G, et al. Streamlined human antibody generation and optimization by exploiting designed immunoglobulin loci in a B cell line. Cell Mol Immunol. 2020;: pubmed publisher
Njau F, Shushakova N, Schenk H, Wulfmeyer V, Bollin R, Menne J, et al. Calcium dobesilate reduces VEGF signaling by interfering with heparan sulfate binding site and protects from vascular complications in diabetic mice. PLoS ONE. 2020;15:e0218494 pubmed publisher
Uslu Ö, Herold J, Kanse S. VEGF-A-Cleavage by FSAP and Inhibition of Neo-Vascularization. Cells. 2019;8: pubmed publisher
Buczek Thomas J, Rich C, Nugent M. Hypoxia Induced Heparan Sulfate Primes the Extracellular Matrix for Endothelial Cell Recruitment by Facilitating VEGF-Fibronectin Interactions. Int J Mol Sci. 2019;20: pubmed publisher
Zhang Y, Yong L, Luo Y, Ding X, Xu D, Gao X, et al. Enhancement of HIFU ablation by sonosensitizer-loading liquid fluorocarbon nanoparticles with pre-targeting in a mouse model. Sci Rep. 2019;9:6982 pubmed publisher
Miller C, Tsuchida C, Zheng Y, Himmelfarb J, Akilesh S. A 3D Human Renal Cell Carcinoma-on-a-Chip for the Study of Tumor Angiogenesis. Neoplasia. 2018;20:610-620 pubmed publisher
Li Y, Hickson J, Ambrosi D, Haasch D, Foster Duke K, Eaton L, et al. ABT-165, a Dual Variable Domain Immunoglobulin (DVD-Ig) Targeting DLL4 and VEGF, Demonstrates Superior Efficacy and Favorable Safety Profiles in Preclinical Models. Mol Cancer Ther. 2018;17:1039-1050 pubmed publisher
Mamer S, Chen S, Weddell J, Palasz A, Wittenkeller A, Kumar M, et al. Discovery of High-Affinity PDGF-VEGFR Interactions: Redefining RTK Dynamics. Sci Rep. 2017;7:16439 pubmed publisher
Malara N, Trunzo V, Musolino G, Aprigliano S, Rotta G, Macrina L, et al. Soluble CD54 induces human endothelial cells ex vivo expansion useful for cardiovascular regeneration and tissue engineering application. Int J Cardiol Heart Vasc. 2015;6:48-53 pubmed publisher
LeBlanc M, Wang W, Chen X, Caberoy N, Guo F, Shen C, et al. Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy. J Exp Med. 2017;214:1029-1047 pubmed publisher
Wang J, Qin B, Chen X, Wagner W, Villanueva F. Ultrasound Molecular Imaging of Angiogenesis Using Vascular Endothelial Growth Factor-Conjugated Microbubbles. Mol Pharm. 2017;14:781-790 pubmed publisher
Ding K, Eaton L, Bowley D, Rieser M, Chang Q, Harris M, et al. Generation and characterization of ABBV642, a dual variable domain immunoglobulin molecule (DVD-Ig) that potently neutralizes VEGF and PDGF-BB and is designed for the treatment of exudative age-related macular degeneration. MAbs. 2017;9:269-284 pubmed publisher
Inoo K, Inagaki R, Fujiwara K, Sasawatari S, Kamigaki T, Nakagawa S, et al. Immunological quality and performance of tumor vessel-targeting CAR-T cells prepared by mRNA-EP for clinical research. Mol Ther Oncolytics. 2016;3:16024 pubmed
Davydova N, Harris N, Roufail S, Paquet Fifield S, Ishaq M, Streltsov V, et al. Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D. J Biol Chem. 2016;291:27265-27278 pubmed publisher
Han K, Chang J, Lee H, Azar D. Proangiogenic Interactions of Vascular Endothelial MMP14 With VEGF Receptor 1 in VEGFA-Mediated Corneal Angiogenesis. Invest Ophthalmol Vis Sci. 2016;57:3313-22 pubmed publisher
Teran M, Nugent M. Synergistic Binding of Vascular Endothelial Growth Factor-A and Its Receptors to Heparin Selectively Modulates Complex Affinity. J Biol Chem. 2015;290:16451-62 pubmed publisher
Fleetwood F, Klint S, Hanze M, Gunneriusson E, Frejd F, StÃ¥hl S, et al. Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity. Sci Rep. 2014;4:7518 pubmed publisher
Maertens L, Erpicum C, Detry B, Blacher S, Lenoir B, Carnet O, et al. Bone marrow-derived mesenchymal stem cells drive lymphangiogenesis. PLoS ONE. 2014;9:e106976 pubmed publisher
Qi J, Ebrahem Q, Ali M, Cutler A, Bell B, Prayson N, et al. Tissue inhibitor of metalloproteinases-3 peptides inhibit angiogenesis and choroidal neovascularization in mice. PLoS ONE. 2013;8:e55667 pubmed publisher
Harris N, Davydova N, Roufail S, Paquet Fifield S, Paavonen K, Karnezis T, et al. The propeptides of VEGF-D determine heparin binding, receptor heterodimerization, and effects on tumor biology. J Biol Chem. 2013;288:8176-86 pubmed publisher
Pfister C, Pfrommer H, Tatagiba M, Roser F. Vascular endothelial growth factor signals through platelet-derived growth factor receptor ? in meningiomas in vitro. Br J Cancer. 2012;107:1702-13 pubmed publisher
Lorenzon E, Colladel R, Andreuzzi E, Marastoni S, Todaro F, Schiappacassi M, et al. MULTIMERIN2 impairs tumor angiogenesis and growth by interfering with VEGF-A/VEGFR2 pathway. Oncogene. 2012;31:3136-47 pubmed publisher
Goyal A, Pal N, Concannon M, Paul M, Doran M, Poluzzi C, et al. Endorepellin, the angiostatic module of perlecan, interacts with both the ?2?1 integrin and vascular endothelial growth factor receptor 2 (VEGFR2): a dual receptor antagonism. J Biol Chem. 2011;286:25947-62 pubmed publisher
Nishiguchi K, Kataoka K, Kachi S, Komeima K, Terasaki H. Regulation of pathologic retinal angiogenesis in mice and inhibition of VEGF-VEGFR2 binding by soluble heparan sulfate. PLoS ONE. 2010;5:e13493 pubmed publisher
Lorquet S, Berndt S, Blacher S, Gengoux E, Peulen O, Maquoi E, et al. Soluble forms of VEGF receptor-1 and -2 promote vascular maturation via mural cell recruitment. FASEB J. 2010;24:3782-95 pubmed publisher
Rennel E, Varey A, Churchill A, Wheatley E, Stewart L, Mather S, et al. VEGF(121)b, a new member of the VEGF(xxx)b family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo. Br J Cancer. 2009;101:1183-93 pubmed publisher
Ponticelli S, Marasco D, Tarallo V, Albuquerque R, Mitola S, Takeda A, et al. Modulation of angiogenesis by a tetrameric tripeptide that antagonizes vascular endothelial growth factor receptor 1. J Biol Chem. 2008;283:34250-9 pubmed publisher
Pan Q, Chathery Y, Wu Y, Rathore N, Tong R, Peale F, et al. Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting. J Biol Chem. 2007;282:24049-56 pubmed
Wirzenius M, Tammela T, Uutela M, He Y, Odorisio T, Zambruno G, et al. Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting. J Exp Med. 2007;204:1431-40 pubmed
Backer M, Levashova Z, Patel V, Jehning B, Claffey K, Blankenberg F, et al. Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes. Nat Med. 2007;13:504-9 pubmed
Lake A, Vassy R, Di Benedetto M, Lavigne D, Le Visage C, Perret G, et al. Low molecular weight fucoidan increases VEGF165-induced endothelial cell migration by enhancing VEGF165 binding to VEGFR-2 and NRP1. J Biol Chem. 2006;281:37844-52 pubmed
Ren W, Markel D, Zhang R, Peng X, Wu B, Monica H, et al. Association between UHMWPE particle-induced inflammatory osteoclastogenesis and expression of RANKL, VEGF, and Flt-1 in vivo. Biomaterials. 2006;27:5161-9 pubmed
Getmanova E, Chen Y, Bloom L, Gokemeijer J, Shamah S, Warikoo V, et al. Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro. Chem Biol. 2006;13:549-56 pubmed
Oliner J, Min H, Leal J, Yu D, Rao S, You E, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell. 2004;6:507-16 pubmed
Seo K, Lee H, Jung B, Ko H, Choi J, Park S, et al. Estrogen enhances angiogenesis through a pathway involving platelet-activating factor-mediated nuclear factor-kappaB activation. Cancer Res. 2004;64:6482-8 pubmed

product information

brand :

R&D Systems

master code :

357-KD/CF

SKU :

357-KD-050/CF

product name :

Recombinant Human VEGFR2/KDR Fc Chimera Protein, CF

unit size :

50 ug

seo description :

The Recombinant Human VEGFR2/KDR Fc Chimera Protein, CF from R&D Systems is derived from NS0. The Recombinant Human VEGFR2/KDR Fc Chimera Protein, CF has been validated for the following applications: Bioactivity.

target :

VEGFR2/KDR/Flk-1

category :

Proteins and Enzymes

buffer :

Lyophilized from a 0.2 ╡m filtered solution in PBS.

conjugate :

Unconjugated

dilution :

Bioactivity

purity :

>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie« Blue Staining.

species :

Human

observed molecular weight :

160-170 kDa, reducing conditions

theoretical molecular weight :

110 kDa (monomer)

gene symbol :

KDR

details of functionality :

Measured by its ability to inhibit the VEGF-dependent proliferation of HUVEC human umbilical vein endothelial cells. The ED50 for this effect is 10-40 ng/mL in the presence of 10 ng/mL recombinant human VEGF165.

endotoxin note :

<0.10 EU per 1 ╡g of the protein by the LAL method.

accessionNumbers :

AAC16450

applications :

Bioactivity

source :

NS0-derived Recombinant Human VEGFR2/KDR Fc Chimera Protein, CF

USD :

443 USD

alt names :

CD309, CD309 antigen, EC 2.7.10, EC 2.7.10.1, Fetal liver kinase 1, fetal liver kinase-1, Flk1, Flk-1, FLK1tyrosine kinase growth factor receptor, KDR, Kinase insert domain receptor, kinase insert domain receptor (a type III receptor tyrosine kinase), KRD1, Ly73, Protein-tyrosine kinase receptor flk-1, soluble VEGFR2, vascular endothelial growth factor receptor 2, VEGF R2, VEGFR, VEGFR2, VEGFR-2

storage :

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 ░C as supplied. 1 month, 2 to 8 ░C under sterile conditions after reconstitution. 3 months, -20 to -70 ░C under sterile conditions after reconstitution.

more info or order :

R&D Systems product webpage